PERTH: AusCann Group Holdings Limited announced Nick Woolf as the new Chief Executive Officer (CEO) effective immediately.

Nick joins AusCann after some 25 years’ experience in the Investment Banking and Life Sciences industries both in Australia and internationally. His previous roles include CEO of Proteolytics, Chief Business Officer of Suda Pharmaceuticals and Chief Financial Officer of PYC Therapeutics.

Nick is a qualified accountant , a Graduate of the Australian Institute of Company Directors (AICD), holds a Graduate Certificate in Management (with Distinction ) from the Australian Institute of Business (AIB)and has a BA (Hons) and MA in Chemistry from Oxford University.

Nick Woolf said, “I am excited joining AusCann at this pivotal point in its development and building on the work already undertaken by IdoKanyonin getting our first product into market and commencing our clinical research programmes”.

Max Johnston, AusCann Chairman, said “we are very fortunate to have been able to secure Nick for the role. He brings with him a proven record of driving commercial success and has extensive cross functional expertise in finance, operations and business development within life sciences as well as investment markets and M&A”.